Snorkel AI Heads Into 2023 With Record Momentum and Growth
18.1.2023 17:00:00 EET | Business Wire | Press release
Snorkel AI, the data-centric AI platform company, today announced record 2022 business momentum, led by triple-digit customer growth. New customer additions included BNY Mellon, Black Swan Data, Georgetown University's Center for Security and Emerging Technology (CSET), and Pixability. Snorkel AI also added five out of the top ten US banks to its customer portfolio and expanded its roster to include a number of government agencies and Fortune 500 companies across financial services, insurance, pharma and healthcare, manufacturing and retail industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005384/en/
Snorkel AI Heads Into 2023 With Record Momentum and Growth (Graphic: Business Wire)
Enterprise data science and machine learning teams use Snorkel Flow, the company’s flagship AI platform powered by programmatic labeling, to accelerate AI application development by 10-100x. Organizations achieve hundreds of thousands to over million dollars in return on investment per project, and unlock net-new use cases for NLP, document processing, automation, analytics, and more blocked by manual labeling.
“The rate of progress in AI is accelerating, especially with foundation models,” said Alex Ratner, CEO and co-founder, Snorkel AI. “However, more enterprises than ever before are effectively blocked by the training data needed to adapt models for their specific use cases and production quality requirements. With our data-centric AI platform, we bridge the gap between enterprise AI and the latest innovations. Our market leadership and growth are clear indicators of the value this unlocks for our customers.”
Snorkel AI continued to innovate in 2022 by announcing the general availability of Snorkel Flow. The company also added a number of data-centric AI capabilities designed to accelerate enterprise AI development with automated labeling, efficient collaboration between data scientists and subject matter experts, and rapid, model-guided iteration.
- Data-centric Foundation Model Development: Workflows to fine-tune foundation models or large language models and use them to build smaller, specialized models deployable for complex, performance-critical enterprise use cases.
- Continuous Model Feedback: Automated model training and integrated analysis to provide near real-time guidance when developing training data.
- Cluster View: Instant creation of embedding-based clusters and auto-generated cluster labeling functions to quickly turn a massive unlabeled dataset into high-quality training data.
- New Studio: Support for a wide range data types and ML tasks such as text and document classification and extraction, PDF and conversational AI pipelines, sequence tagging, and more.
Additional 2022 highlights included:
- Expanded Partnership Ecosystem: Snorkel AI deepened partnerships across the enterprise AI ecosystem including Microsoft Azure AI Services, Google BigQuery and Vertex AI, Snowflake, Aimpoint Digital, Four Inc. and more.
- Hosted Largest Data-Centric AI Conference: Future of Data-Centric AI 2022 brought together thousands of leaders of data science and analytics teams, AI/ML practitioners, researchers, and students. The three-day event featured over 50 sessions from Apple, AstraZeneca, CIA, Capital One, Comcast, Databricks, Ford, Google, JPMorgan Chase, Meta, NVIDIA, Orange, State Farm, and more.
- Published Breakthrough Research: Snorkel AI Research published over 30 papers at NeurIPS, ICLR, ACL and more with academic partners at Brown University, Stanford University, University of Washington, and University of Wisconsin-Madison. The research team also contributed to major initiatives such as the WRENCH benchmark and BigScience advancing the state-of-the-art for data-centric AI.
- Received Industry and Analyst Recognition: Snorkel AI was named a 2022 Cool Vendor in their AI Core Technologies report and ranked in CBInsights AI 100: Most Promising AI Startups 2022. The company was also recognized by VentureBeat for their AI innovation award for Applied AI. Additionally, Snorkel AI was featured in WingVC: Top 30 Enterprise Tech and CRN: Top 10 Hottest AI Startups and Emerging Vendors lists.
About Snorkel AI
Founded by a team spun out of the Stanford AI Lab, Snorkel AI makes AI application development fast and practical by unlocking the power of machine learning without the bottleneck of manually-labeled training data. Snorkel Flow is the first data-centric AI platform powered by programmatic labeling. Backed by Addition, Greylock, GV, In-Q-Tel, Lightspeed Venture Partners and funds and accounts managed by BlackRock, the company is based in Palo Alto. For more information on Snorkel AI, please visit: https://www.snorkel.ai/ or follow @SnorkelAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005384/en/
Contact information
Media Contact
Ignacio Ramirez
ignacio.ramirez@snorkel.ai
415-517-6708
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom